Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Incidence of Allergic Reactions with Plenaxis in Prostate Cancer
NCT00103623Phase 4Suspended
- Sponsor
- Praecis Pharmaceuticals Incorporated
- Start
- Jun 2004
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of abarelix in prostate cancer (PCa), sponsored by Praecis Pharmaceuticals Incorporated. Started Jun 2004; status: suspended.
02
Drugs
abarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00103623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00103623.